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Amended proposal for a 
COUNCIL REGULATION (EC) 
AMENDING REGULATION (EC) No 297/95 
ON FEES PAY  ABLE TO THE EUROPEAN AGENCY 
FOR THE EVALUATION OF MEDICINAL PRODUCTS 
(presented by the Commission pursuant to Article 189 a (2) 
of  the EC-Treaty) Explanatory Memorandum 
On 7 October 1998  the European  Parliament adopted an opinion on the proposal  for a 
Council  Regulation  on  fees  payable  to  the  European  Agency  for  the  evaluation  of 
medicinal products. 
The Commission accepted amendments I 0,  II  and  16.  In  addition, the Commission is 
also  incorporating  in  this  proposal - already  partially  amended or subject to  possible 
amendment- the following amendments:  amendment 12  (in the event of the fee  being 
increased on initiation of  the arbitration procedure in  respect of  a marketing authorisation 
l(>r a vdcrinary medicinal product, such an  increase is  to  remain pegged within a ceiling 
or H  'l I 20 000), anwudmcnt  I~ (any increase in  the additional  Icc  i(>r  an application to 
amend or extend illl existing MLR  is  to remain pegged within a ceiling or ECU  15 000) 
and  amendment  14 (introduction of the principle of maximum fees  lor applications  for 
scientific advice). 
The Commission has not adopted amendments I to 9 for the following reasons: 
Amendment I 
Amendments 
2,3,5,1> and 7 
Amendment 4 
Amendments 
8 and 9 
The  Commission  is  ·opposed  to  a  change  in  the  legal  basis  of the 
proposed text, on the grounds that the derived legal basis (Article I 0 of 
Regulation (EC) No  297/95) is perfectly appropriate.  The Commission 
would  also  stress  that  the  principle  of  consulting  the  European 
Parliament was preserved at its  request,  when  the derived  legal  basis 
was introduced. 
These amendments do not speci lically concern the levels and structure 
of the  fees  payable  to  the  European  Agency  for  the  evaluation  of 
medicinal  products  but  refer  to  the  budget  rules  applicable  to  the 
Agency.  Furthermore,  these  aspects  arc  also  the  subject of a  draft 
horizontal regulation covering all agencies currently under discussion. 
The replacement of  the ecu by the euro throughout all Community texts 
will need to be the subject of  a horizontal text. 
The Commission is opposed to the reintroduction of ceilings for  fees 
directly  linked  to  the  granting of marketing  authorisations  under the 
centralised procedure.  These ceilings cannot be justified either in terms 
of the  service provided  by the  Agency  or on  public  health  grounds. 
Indeed, the principles governing the rational use of medicinal products 
preclude the proliferation of  different pharmaceutical forms of  the same 
medicinal product. T 
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r:ollowing  the  opmwn  of  lhc  European  l'arliamcnl  or  7  Oclobcr  I'!'!X.  the  initial 
l 'onunission proposal (('OM (I  '!'!X) 21  linal) is hereby amended as il>llows: 
f\mcnde<l text 
ARTII'I.E I. POINT 2 
,\  rt ie It- it .1 ). point a). sin1•.k subparagraph a) (new) (I{ cgu  Ia! ion ( 1·:< ·)  No 1 .'117 /11)) 
In  the event or tlws:nne  :llllL'ndm~nl heing 
introduLTd,  this  li.·L·  shall  cover  all 
aulht_,risl·d  siH.'Ilglhs,  phantWl'l'U!i~al  ll.,nn_s 
H~l_<J _  _pf_l~~~ll!Hl  ~(, I)S. 
ARTICLE I. POINT 2 
Article 3(2), point b), single subparagraph a) {new) (Regulation (EC) No 297/95) 
In the event of the same amendment being 
introduced.  this  fcc  shall  cover  all 
n_uth(!.ri_~~~  stn;_~!glhs. J~hi~fn11_t~_cuticujJ(~pn~ 
~~nd_prc~c~!llH  i~ ms. 
ART  II 'I.E I. !'OINT.' 
Article 'i( ~  ).  point a). singk suhpamgraph a) (new) (Regulation ( H ') No 2117 /'I)) 
In  th~ event of the  sanu:  ~_llllL'llll!.l_~~pl  h~il_)g 
jnlrodueed  this  Icc  sl!all  cover  all 
authorised strengths, pharmaceutical forms 
and presentations. 
ARTICLE I, POINT 2 
Article 5(2), point b). third subparal.\raph (new) (Regulation (E(') No 2'!7/'15) 
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